For instance, increased expression of IGF-I and IGF-IR has been observed in AML patient samples and cell lines, and correlates with enhanced PI3K/AKT pathway activation and poor clinical outcomes (12, 13). This evidence concerns the gene IGF1 and acute myeloid leukemia.